|
|
 Previous Article | Table of Contents | Next Article 
Pharmacokinetics and immunomodulatory properties of intravenously
administered recombinant human interleukin-10 in healthy volunteers
RD Huhn, E Radwanski, SM O'Connell, MG Sturgill, L Clarke, RP Cody, MB Affrime and DL Cutler
Department of Medicine, UMDNJ-Robert Wood Johnson Medical School, New
Brunswick 08903-0019, USA.
Normal volunteers received single doses of recombinant human interleukin-10
(rhIL-10; n = 6 per group) or placebo (n = 3 per group) by intravenous
injection to characterize pharmacokinetics, tolerability, and
immunomodulatory effects. Dosages were 0.1, 0.5, 1.0, 2.5, 5.0, 10.0, 25.0,
50.0, and 100.0 micrograms/kg. Dose-related adverse effects consisted of a
mild-to-moderate flu-like syndrome characterized by fever with chills,
headache, and myalgias at the highest dose. The mean terminal phase t1/2
ranged from 2.3 +/- 0.5 to 3.7 +/- 0.8 hours. Dose-related effects of
rhIL-10 included transient increases of circulating neutrophils and
monocytes and decreases of lymphocytes. rhIL-10 markedly suppressed, in a
time- and dose-dependent manner, the synthesis of the inflammatory
cytokines IL-1 beta and tumor necrosis factor alpha by whole blood
stimulated ex vivo with bacterial lipopolysaccharide. Circulating numbers
of CD14+/HLA-DR+ cells at 24 hours after the dose were increased in a
dose-dependent manner. Effects on expression of HLA-DR by CD14+ cells were
variable. There was no apparent effect on HLA-DR expression by CD20+ cells.
The immunomodulatory effects of rhIL-10 merit further clinical
investigation.
Volume 87,
Issue 2,
pp. 699-705,
01/15/1996
Copyright © 1996 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
P. C. Ng, K. Li, T. F. Leung, R. P.O. Wong, G. Li, K. M. Chui, E. Wong, F. W.T. Cheng, and T. F. Fok
Early Prediction of Sepsis-Induced Disseminated Intravascular Coagulation with Interleukin-10, Interleukin-6, and RANTES in Preterm Infants
Clin. Chem.,
June 1, 2006;
52(6):
1181 - 1189.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. K. Dahle, A. E. Myhre, A. O. Aasen, and J. E. Wang
Effects of Forskolin on Kupffer Cell Production of Interleukin-10 and Tumor Necrosis Factor Alpha Differ from Those of Endogenous Adenylyl Cyclase Activators: Possible Role for Adenylyl Cyclase 9
Infect. Immun.,
November 1, 2005;
73(11):
7290 - 7296.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. Deleuze, J. Lefort, M. F. Bureau, D. Scherman, and B. B. Vargaftig
LPS-induced bronchial hyperreactivity: interference by mIL-10 differs according to site of delivery
Am J Physiol Lung Cell Mol Physiol,
January 1, 2004;
286(1):
L98 - L105.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Asadullah, W. Sterry, and H. D. Volk
Interleukin-10 Therapy--Review of a New Approach
Pharmacol. Rev.,
June 1, 2003;
55(2):
241 - 269.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Vila, J. Castillo, A. Davalos, A. Esteve, A. M. Planas, and A. Chamorro
Levels of Anti-Inflammatory Cytokines and Neurological Worsening in Acute Ischemic Stroke
Stroke,
March 1, 2003;
34(3):
671 - 675.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Q. Latifi, M. A. O'Riordan, and A. D. Levine
Interleukin-10 Controls the Onset of Irreversible Septic Shock
Infect. Immun.,
August 1, 2002;
70(8):
4441 - 4446.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. K. Adams and B. L. Tepperman
Colonic production and expression of IL-4, IL-6, and IL-10 in neonatal suckling rats after LPS challenge
Am J Physiol Gastrointest Liver Physiol,
April 1, 2001;
280(4):
G755 - G762.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. E. Wigginton and D. Kirschner
A Model to Predict Cell-Mediated Immune Regulatory Mechanisms During Human Infection with Mycobacterium tuberculosis
J. Immunol.,
February 1, 2001;
166(3):
1951 - 1967.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Adib-Conquy, A.-F. Petit, C. Marie, C. Fitting, and J.-M. Cavaillon
Paradoxical priming effects of IL-10 on cytokine production
Int. Immunol.,
May 1, 1999;
11(5):
689 - 698.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J.-M. Cavaillon, M. Adib-Conquy, C. Marie, and C. Fitting
Hyporesponsiveness in leukocytes in sepsis: in vitro models reveal paradoxical effects of IL-10
Innate Immunity,
February 1, 1999;
5(1-2):
81 - 85.
[Abstract]
[PDF]
|
|
|
|
|
|
|
F. Muller, P. Aukrust, I. Nordoy, and S. S. Froland
Possible Role of Interleukin-10 (IL-10) and CD40 Ligand Expression in the Pathogenesis of Hypergammaglobulinemia in Human Immunodeficiency Virus Infection: Modulation of IL-10 and Ig Production After Intravenous Ig Infusion
Blood,
November 15, 1998;
92(10):
3721 - 3729.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. J. Downing, R. M. Strieter, A. M. Kadell, C. A. Wilke, J. C. Austin, B. D. Hare, M. D. Burdick, L. J. Greenfield, and T. W. Wakefield
IL-10 Regulates Thrombus-Induced Vein Wall Inflammation and Thrombosis
J. Immunol.,
August 1, 1998;
161(3):
1471 - 1476.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Brunetti, A. Colasante, N. Mascetra, M. Piantelli, P. Musiani, and F. B. Aiello
IL-10 Synergizes with Dexamethasone in Inhibiting Human T Cell Proliferation
J. Pharmacol. Exp. Ther.,
May 1, 1998;
285(2):
915 - 919.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
H. L. Dickensheets, S. L. Freeman, M. F. Smith Jr, and R. P. Donnelly
Interleukin-10 Upregulates Tumor Necrosis Factor Receptor Type-II (p75) Gene Expression in Endotoxin-Stimulated Human Monocytes
Blood,
November 15, 1997;
90(10):
4162 - 4171.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
